Kardigan, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for cardiovascular diseases with high unmet medical needs. The company's business model centers on in-licensing and advancing late-stage therapeutic candidates that target the underlying pathophysiology of heart conditions, moving beyond traditional symptom management. Kardigan's pipeline includes three primary clinical-stage programs: danicamtiv, an oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM); ataciguat, a soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (CAVS); and tonlamarsen, an antisense oligonucleotide for acute severe hypertension (ASH). A key differentiator for Kardigan is its proprietary "Cardiac Intelligence" platform, which incorporates Prolaio's cardiovascular data collection and analytics technology. This platform utilizes artificial intelligence, FDA-cleared algorithms, and high-density patient data from wearable devices to enhance clinical study design, improve patient responder matching, and track efficacy. By integrating deep cardiovascular biology with advanced analytics, Kardigan aims to accelerate drug development and increase the probability of clinical success. The company operates primarily in the United States, with offices in Princeton, New Jersey, and South San Francisco, California. As a pre-revenue clinical-stage biotech, Kardigan relies on venture capital and public market funding to advance its pipeline toward commercialization.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!